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Background. The lipid profiles of patients with overweight, obesity and healthy individuals, the citizens of 
Transcarpathia valley regions were analysed.
Objective. The study was aimed at evaluation of dyslipidaemia frequency in patients with overweight and 
obesity, determination of expedience of statins prescription.
Methods. All patients were divided into 2 groups: group 1 – patients with overweight; group 2 – patients 
with obesity of I and II degree. Estimation of lipid profile parameters was conducted by means of spectrophotometric 
device SIEMENS Dimension RxL Max. Statistical analysis of the data was conducted using Microsoft Excel 2007.
Results. The patients with obesity had higher level of total cholesterol (6.03±0.53 mmol/l), lower HDL-C 
(1.15±0.07 mmol/l) and higher level of LDL-C (4.19±0.46 mmol/l) compare with overweight patients. In 46% of 
patients with overweight, dyslipidaemia was evidenced and required correction, 27% of them had high CVR and 
needed statin therapy, 19% of people with obesity had moderate CVR and didn’t need statins. 77% of obese 
patients needed lipid correction, 54% of them with very high and averagely high level of CVR required statin 
therapy; 23% of people with obesity had moderate CVR and did not need statins.
Conclusions. In the studied overweight and obese patients, atherogenic dyslipidaemia was established in 
46% and 77% of cases respectively. Correction of dyslipidaemia with statin was compulsory for 27% of patients 
with overweight and for 54% with obesity. 
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Introduction 
in 2000, the whO first suggested using the 
term ‘epidemic’ to distinguish the situation with 
obesity prevailing in the world; it was recognized 
that the number of people with overweight and 
obesity is progressively increasing.
Over the last 35 years the number of obese 
patients has increased twice, and over the last 
10 years it increased by 75%. According to WHO 
data in 2003 there were 1.7 billion of the adult 
population suffering from overweight (BMi≥25 
kg/m2), the statistics in 2014 announced a new 
data: there were more than 1.9 billion people 
with overweight and obesity [1].
In 2016 the results of a meta-analysis on 
the dynamics of BMI in adults of over 18 years 
old bet ween 1975 and 2014 were published. 
1698 data on population studies was analysed, 
which inclu ded 19.2 million people from 186 
countries. The increase of average BMI from 
21.7±0.4 kg/m2 to 24.2±0.2 kg/m2 for men and 
from 22.1±0.4 kg/m2 to 24.4±0.2 kg/m2 for 
women was proved [2].
The negative effect of obesity on population 
is established: this pathology correlates with 
increased morbidity, mortality, quality of life, 
and is a significant socioeconomic burden for 
the world [3]. Several studies prove that obesity 
increases the cost of medical care and worsens 
the quality of life [4].
To reduce mortality from cardiovascular 
diseases in people aged under 65, the Council 
of Europe in 2002 declared a Plan “Heart of 
Europe”, according to which it is necessary to 
reduce cholesterol level in the population by 
less than 5.0 mmol/l, lower blood pressure in 
the population to a level of <140/90 mm Hg., 
reduce the number of smokers by 1% per 1 year. 
Thus, by 2020 the mortality rate should de-
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crease by 40% (2.4% per year). To achieve this 
goal, primary care physicians must reorient to 
early detection of lipid metabolism disorders, 
their adequate correction and prevention of 
atherosclerosis associated with cardiovascular 
diseases and their complications [5].
In most patients with obesity such lipid 
disorders are observed: rising of small particles 
of low density lipoprotein (LDL) in blood plasma 
[5, 6, 7], which is often associated with increased 
levels of triglycerides (TG) and decreased level 
of high-density lipoprotein cholesterol (HDL 
cholesterol) [5].
Algorithm development for selection of 
patients for statins therapy, adequate drug 
choice and its efficacy control, evaluation of 
target level of cholesterol are the topical matter 
for a family doctor today.
However, the questions ‘how often sub cli-
nical dyslipidaemia in obese patients is re-
vealed’, and ‘how reasonable the prescription 
of statins for these patients is’ are still open, 
because of the absence of supply for routine 
lipid profile determination in the practice of 
family doctors in Ukraine.
The study was aimed at evaluation of dysli-
pidaemia frequency in patients with overweight 
and obesity, determination of the expedience 
of statins prescription.
Methods
40 individuals who attended clinics of family 
medicine in Uzhhorod from October to Decem-
ber 2015 were examined.
We analysed the following data in the 
examined persons: age, sex, level of total car-
diovascular risk (CVR), body mass index (BMI), 
total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-C), low density lipoprotein 
cholesterol (LDL-C), triglycerides (TG), athero-
genic coefficient (aC). Estimation of lipid profile 
parameters was conducted by means of spec-
tro photometric device SIEMENS Dimension RxL 
Max. 
The study was approved by the Ethics Com-
mittee of the Transcarpathian Regional Clinical 
Cardiology Dispensary. The patient had to sign 
the informed consent to involvement in the 
research. 
For diagnosis of the overweight or obese 
we used a body mass index, which was cal-
culated as the ratio of body weight to height 
squared (kg/m2). The persons, whose BMI was 
from 25 to 29.99 kg/m2 composed the group of 
patients with overweight. The persons with BMI 
from 30 to 34.99 kg/m2 were diagnosed with 
obesity I degree, in the persons with BMI from 
35 to 39.99 kg/m2 obesity II degree was esta-
blished. the results of lipid profile were inter-
preted according to guidelines of the ESC and 
target lipid levels of patients with different CVR.
all patients were divided into 2 groups: 
group 1 – patients with overweight; group 2 – 
patients with obesity of I and II degree (he-
reinafter patients with obesity). The share of 
patients with overweight was 55% (22 people), 
with obesity – 45% (18 persons). Due to the 
terms and conditions of the research, only 
those patients, who did not take statins for at 
least one month before the date of screening, 
took part in the study.
Patients’ data was normally distributed. 
Statistical analysis of the data: the t-test and 
Pearson rank correlation coefficient, was con-
ducted using Microsoft Excel 2007.
Results
The average age of group 1 patients was 
57.2±1.2 years old, BMI 27.06±0.42 kg/m2. The 
average age of group 2patients was 59.7±1.1 
years old, BMI 35.9±1.17 kg/m2.
Patients with obesity had the following 
differences in lipid spectrum compared with 
those who were overweight: higher level of 
total cholesterol (6.03±0.53 mmol/l vs 4.76±0.23 
mmol/l, p=0.048), lower HDL-C level (1.15±0.07 
mmol/l and 1.51±0.12 mmol/l, p=0.02) and 
higher level of LDL-C (4.19±0.46 mmol/l and 
2.89±0.21 mmol/l, p=0.026).
In the group 1, among all, who required 
correction of lipid spectrum, 19% of patients 
had moderate CVR and didn't need statin 
therapy because the average level of LDL-C was 
2.5±0.13 mmol/l; respectively, 27% had in-
creased CVR and average level of LDL-C was 
3.4±0.21 mmol/l and they needed statin 
therapy.
Among the obese 77% of patients required 
lipid correction. 21% of group 2 patients had a 
very high average level of CVR because LDL-C 
level was 4.4±0.32 mmol/l and they needed 
correction of lipid profile with statins; 33% of 
patients had high CVR with an average level of 
LDL cholesterol 3.7±0.51 mmol/l and also 
needed statin therapy; 23% of patients with 
obesity had moderate CVR and did not need 
statins (Fig.1).
in addition to determination of significant 
differences between different groups, we also 
conducted correlation analysis of the groups of 
patients. In group 1 a direct average relation-
ship was revealed between: the level of total 
a. V. Kedyk et al.
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cholesterol and BMI (r=0.5), BMI and LDL cho-
lesterol (r =0.4), BMI and TG (r=0.56), BMI and 
atherogenic ratio (r=0.34), inverse middle rela-
tionship between age and the level of HDL 
cholesterol (r=-0.52). Similar correlations were 
found in the group 2: between BMi and total 
cholesterol (r=0.42), BMI and LDL cholesterol 
(r=0.37), BMI and TG (r=0.46). 
Discussion
thus, with increase of BMi, lipid profile got 
worse: the levels of total cholesterol and lDl 
cholesterol increased and of HDL cholesterol 
decreased. According to the literature [8,9, 10], 
in patients with overweight and obesity most 
often such lipid disorders are found: rising of 
small particles of LDL in blood plasma, which is 
often associated with increased level of TG and 
decreased level of HDL-C [6]. According to the 
Framingham Heart Study about 10% of patients 
with overweight have increased blood concen-
trations of cholesterol by 0.3 mmol/l. In young 
patients with overweight the increased level of 
cholesterol was twice more than in people of 
the same age with normal weight. According 
to the results of population survey conducted 
in the national Scientific Center “M.D. Straz-
hesko Institute of Cardiology” MAS of Ukraine; 
the occurrence of hypercholesterolemia in 
patients with overweight is 65%, 70% in the 
obese, and only 40% in people with normal 
weight [10].
The method of dyslipidaemia correction 
was chosen according to the recommendations 
of ESC/AHA and Association of Cardiologists of 
Ukraine. 
46% of patients with overweight had dys-
lipidaemia, which required correction: lifestyle 
modification in 19% and/or statin therapy in 
27%.
Thus, with BMI levels increase the levels of 
total cholesterol, lDl-C and tg significantly 
increase, in addition in patients of the group 1 
HDL-C level decreased with age.
Conclusions
In the examined overweight and obesity 
patients, atherogenic dyslipidaemia was estab-
lished in 46% and 77% of cases respectively. 
Correction of dyslipidaemia by statin was 
compulsory for 27% of patients with overweight 
and 54% with obesity. 
Regardless of gender and age, in the pa-
tients with increased BMI level, the increased 
levels of total cholesterol, LDL cholesterol and 
atherogenic factor were observed.
Fig. 1. Percentage of the obese with different cardio-vascular risks and lipid correction is compulsory.
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